Document is current
Any future updates will be listed below
-
Authors
Gierthmuehlen, Mortimer https://orcid.org/0000-0001-8575-6445
Seidel, Sabine https://orcid.org/0000-0002-1671-3297
Thon, Niklas https://orcid.org/0000-0003-0011-5281
Seliger, Corinna https://orcid.org/0000-0002-4923-4495
-
Clinical Trials BETA
Clinical trials referenced in this document:
drks00036323 at German Clinical Trials RegisterDocuments that mention this clinical trial
Transcutaneous Auricular Vagal Nerve Stimulation for the Treatment of the Fatigue Syndrome in Patients with Primary CNS Lymphoma – A Protocol for a Randomized and Controlled Single Center Clinical Trial
https://doi.org/10.1007/s12325-025-03237-0
-
Funding
Funding for this research was provided by:
Medizinische Fakultät, Ruhr-Universität Bochum (F1087-2024)
Ruhr-Universität Bochum
- License Information
-
More Information
Article History
Received: 7 March 2025
Accepted: 7 May 2025
First Online: 7 June 2025
Declarations
:
: Mortimer Gierthmuehlen: founder and consultant of Neuroloop GmbH, which develops an invasive vagal nerve stimulator against arterial hypertension. Sabine Seidel, Corinna Seliger and Niklas Thon have nothing to disclose.
: This trial received ethical approval from the Ethics Commission Westfalen Lippe (Reference number: 2024–368-f-S) on 19/09/2024. The approved version of the study protocol is version 2. The study was designed in accordance with Good Clinical Practice (GCP), the principles outlined in the Declaration of Helsinki, and established professional conduct standards. Before enrollment, participants will receive detailed information about the study and provide written informed consent. The findings of this randomized pilot study will be disseminated through peer-reviewed publications and conference presentations. This protocol was developed following the Standard Protocol Items for Clinical Trials (SPIRIT) guidelines.
